行情

ENTA

ENTA

Enanta制药
NASDAQ

实时行情|Nasdaq Last Sale

68.97
-0.92
-1.32%
已收盘, 17:07 09/17 EDT
开盘
69.64
昨收
69.89
最高
70.49
最低
68.39
成交量
12.02万
成交额
--
52周最高
106.80
52周最低
63.37
市值
13.57亿
市盈率(TTM)
22.38
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ENTA 新闻

  • 日本社交巨头Line推出加密交易平台Bitmax
  • TechWeb.40分钟前
  • WeWork拟今年完成IPO:估值缩水八成,创始人表悔意
  • 澎湃新闻.46分钟前
  • 财经天下:IMF新掌门将面临哪些挑战?
  • 中国新闻网.50分钟前
  • 13家大型投行前瞻:美联储料降息25个基点 微调声明
  • 汇通网.55分钟前

更多

所属板块

生物技术和医学研究
+0.26%
制药与医学研究
+0.57%

热门股票

名称
价格
涨跌幅

ENTA 简况

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
展开

Webull提供Enanta Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。